Chordate Medical obtains trademark registration for Ozilia in the US
Chordate Medical announces that the United States Patent and Trademark Office (USPTO) has approved the company’s application to register the trademark Ozilia in the U.S.
– Securing U.S. trademark registration is, of course, an important part of our intellectual property, says CEO Anders Weilandt.
Chordate Medical has developed a neuromodulation treatment for chronic migraine and rhinitis, leveraging a medtech platform that delivers oscillatory stimulation. Formerly known as Kinetic Oscillation Stimulation (K.O.S.), the treatment was rebranded as Ozilia in 2023 as part of the company’s commercialisation strategy. The new trademark, Ozilia, was chosen to symbolise freedom while also referencing “oscillation” — the core of the company’s technology.
Ozilia now registered in five countries and the EU
The U.S. registration is the fifth national registration under the Madrid Protocol. The trademark is already protected in Israel, Japan, China, and the UK, as well as the European Union since 2023. An application for registration in Brazil is currently under review.
– The OZILIA trademark has been well received by the market, and protecting it through registrations is part of our IP strategy aimed at building long-term value in the company and making the business more attractive to potential buyers, says Anders Weilandt, CEO of Chordate Medical.
Q&A with CEO: how Chordate Medical strengthens its global position
BioStock reached out to CEO Anders Weilandt to gain deeper insights into the recent trademark developments and the company’s strategy.
The Ozilia brand is now registered in five countries, including the United States, as well as in the EU. What does this mean for Chordate Medical’s long-term strategy?
– A cornerstone of our strategy is that our portfolio of intellectual property, including patents and trademarks, represents a significant part of the company’s value – something a potential buyer of the business will certainly assess. Securing U.S. trademark registration is, of course, an important part of our intellectual property.
Ozilia replaced the previous name K.O.S. What was behind the decision to rebrand the treatment?
– K.O.S. is an abbreviation of the technology. We determined that the product needed its own trademark – not least to create recognition and a positive emotional response from our patients. In retrospect, we can conclude that it was a good decision, and that Ozilia has actually performed better than we had hoped.
You have previously announced that you are working to obtain market approval in the U.S. from the FDA. How is that process progressing?
– Since we are now in the final strategic phase of finding a buyer for the business, we are focusing all resources – and thus costs – on that process. The paused work with the FDA can be resumed at any time, either by us or by the future owner of the business.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
